These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 27196782)
1. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models. Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma. Du Z; Caenepeel S; Shen Y; Rex K; Zhang Y; He Y; Tang ET; Wang O; Zhong W; Zhou H; Huang J; Huang E; Hu L; Coxon A; Zhang M Mol Cancer Ther; 2016 Jun; 15(6):1227-37. PubMed ID: 27196749 [TBL] [Abstract][Full Text] [Related]
3. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704 [TBL] [Abstract][Full Text] [Related]
4. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533 [TBL] [Abstract][Full Text] [Related]
5. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694 [TBL] [Abstract][Full Text] [Related]
6. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501 [TBL] [Abstract][Full Text] [Related]
7. The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Egile C; Kenigsberg M; Delaisi C; Bégassat F; Do-Vale V; Mestadier J; Bonche F; Bénard T; Nicolas JP; Valence S; Lefranc C; Francesconi E; Castell C; Lefebvre AM; Nemecek C; Calvet L; Goulaouic H Mol Cancer Ther; 2015 Feb; 14(2):384-94. PubMed ID: 25504634 [TBL] [Abstract][Full Text] [Related]
8. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395 [TBL] [Abstract][Full Text] [Related]
9. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845 [TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. Ai J; Chen Y; Peng X; Ji Y; Xi Y; Shen Y; Yang X; Su Y; Sun Y; Gao Y; Ma Y; Xiong B; Shen J; Ding J; Geng M Mol Cancer Ther; 2018 Apr; 17(4):751-762. PubMed ID: 29237805 [TBL] [Abstract][Full Text] [Related]
11. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Buchanan SG; Hendle J; Lee PS; Smith CR; Bounaud PY; Jessen KA; Tang CM; Huser NH; Felce JD; Froning KJ; Peterman MC; Aubol BE; Gessert SF; Sauder JM; Schwinn KD; Russell M; Rooney IA; Adams J; Leon BC; Do TH; Blaney JM; Sprengeler PA; Thompson DA; Smyth L; Pelletier LA; Atwell S; Holme K; Wasserman SR; Emtage S; Burley SK; Reich SH Mol Cancer Ther; 2009 Dec; 8(12):3181-90. PubMed ID: 19934279 [TBL] [Abstract][Full Text] [Related]
12. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Yan SB; Peek VL; Ajamie R; Buchanan SG; Graff JR; Heidler SA; Hui YH; Huss KL; Konicek BW; Manro JR; Shih C; Stewart JA; Stewart TR; Stout SL; Uhlik MT; Um SL; Wang Y; Wu W; Yan L; Yang WJ; Zhong B; Walgren RA Invest New Drugs; 2013 Aug; 31(4):833-44. PubMed ID: 23275061 [TBL] [Abstract][Full Text] [Related]
13. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor. Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914 [TBL] [Abstract][Full Text] [Related]
14. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145 [TBL] [Abstract][Full Text] [Related]
15. Acquired Resistance to a MET Antibody Pollmann SE; Calvert VS; Rao S; Boca SM; Madhavan S; Horak ID; Kjaer A; Petricoin EF; Kragh M; Poulsen TT Mol Cancer Ther; 2018 Jun; 17(6):1259-1270. PubMed ID: 29545332 [TBL] [Abstract][Full Text] [Related]
16. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells. Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364 [TBL] [Abstract][Full Text] [Related]
17. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767 [TBL] [Abstract][Full Text] [Related]
18. MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors. Smith MA; Licata T; Lakhani A; Garcia MV; Schildhaus HU; Vuaroqueaux V; Halmos B; Borczuk AC; Chen YA; Creelan BC; Boyle TA; Haura EB Clin Cancer Res; 2017 Nov; 23(22):7084-7096. PubMed ID: 28855353 [No Abstract] [Full Text] [Related]
19. Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy. Kim JS; Kim MY; Hong S Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892160 [TBL] [Abstract][Full Text] [Related]
20. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Liu X; Wang Q; Yang G; Marando C; Koblish HK; Hall LM; Fridman JS; Behshad E; Wynn R; Li Y; Boer J; Diamond S; He C; Xu M; Zhuo J; Yao W; Newton RC; Scherle PA Clin Cancer Res; 2011 Nov; 17(22):7127-38. PubMed ID: 21918175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]